Ultragenyx Announces Stock Units for New Executives
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare and ultrarare diseases, has made an important announcement regarding an inducement grant. The company has awarded a total of 37,975 restricted stock units to 12 newly hired non-executive officers. This decision received approval from the compensation committee of the board of directors and is in line with the Ultragenyx Employment Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Details of the Inducement Grant
The newly awarded restricted stock units will vest over a four-year period. Specifically, 25% of the shares will become available on each anniversary of the grant date, contingent upon the employee's continued employment with Ultragenyx at those times. This structure aims to encourage retention among the new team members, fostering a stable workforce committed to the company's mission.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is dedicated to advancing biopharmaceutical innovations aimed at treating serious rare and ultrarare genetic diseases. The company has established a strong portfolio of approved therapies and various product candidates that specifically target significant medical needs where effective treatment options are often lacking. By concentrating on diseases with clear biological targets for treatment, Ultragenyx strives to create new solutions within the healthcare landscape.
Dedicated Leadership in Rare Disease Therapeutics
The management team at Ultragenyx possesses extensive experience in the realm of rare disease therapeutics. Their strategic approach is rooted in efficient drug development principles, with a focus on delivering safe and effective therapies in a timely manner. Ultimately, their goal is to provide essential care to patients facing life-altering conditions.
Commitment to Patients and Innovation
Ultragenyx's strategy is centered around its commitment to patients and the pressing need for effective treatment alternatives for rare diseases. The company is constantly exploring innovative ways to improve therapy delivery, ensuring that advancements in medicine reach those who need them most. This dedication influences every aspect of their operations, from research and development to clinical trials.
Contact Information
For more information about Ultragenyx and its initiatives, please reach out to:
Investors & Media
Joshua Higa
(415) 475-6370
Frequently Asked Questions
What is the purpose of the restricted stock units granted by Ultragenyx?
The restricted stock units are designed to incentivize newly hired executive officers and encourage retention within the company.
How does the vesting schedule for the stock units work?
The stock units vest over a four-year period, with 25% becoming available on each anniversary of the grant date, contingent upon the employee's continued employment.
What is Ultragenyx Pharmaceutical Inc. known for?
Ultragenyx is recognized for its focus on developing therapies for serious rare and ultrarare genetic diseases.
Who is part of the management team at Ultragenyx?
The management team consists of experienced professionals who specialize in rare disease therapeutics and innovative drug development.
What is the company’s mission regarding patient care?
Ultragenyx aims to provide safe and effective therapies for patients suffering from rare diseases, addressing significant unmet medical needs.